Social Media Ideas for Alzheimer's Drug Trial

New Alzheimer’s drug could stop disease

Major trial begins for ‘game changer’ medicine that has potential to halt degenerative condition before symptoms show

An experimental Alzheimer's drug is showing some promise

An experimental drug might help slow early Alzheimer's disease in a markedly different way than today's treatments — by lowering levels of a brain protein called tau, researchers r...

ATP Platform Adaptive Trial Speeds Up Dementia Research

UCSF launches the historic ATP clinical trial, testing a combination of donanemab and the AADvac1 vaccine to treat pre-symptomatic Alzheimer's.

An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches

WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called...

An experimental Alzheimer's drug shows some promise as researchers hunt new approaches

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau.

New experimental drug shows promise in slowing early Alzheimer’s

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

Experimental Alzheimer's drug shows promise targeting brain protein tau in study

An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers r...

An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches

WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called...

Promising New Drug Shows Potential to Slow Alzheimer’s Progression

In a groundbreaking advancement in Alzheimer’s disease research, a team led by Professor Ursula Quitterer at ETH Zurich has developed a chemical compound that shows remarkable prom...

New Math Method Inflates Alzheimer’s Drug Success by 29x

A critical research lette exposes severe flaws in "quantile aggregation", a statistical technique recently used by pharmaceutical researchers to evaluate the drug donanemab.

Could an investigational drug that targets DNA damage help treat Alzheimer's disease?

Using a mouse model of Alzheimer's disease, investigators found that treatment with KCL-286, a molecule that activates the retinoic acid receptor-β�(RARβ), e...

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s st...

Woman with dementia shares first words in five years after taking controversial drug

Woman with dementia shares first words in five years after taking controversial drug

Woman with dementia shares first words in five years after taking controversial drug

Woman with dementia shares first words in five years after taking controversial drug

An Alzheimer’s Patient Recovered Speech and Memory After One Dose of This Experimental Drug

An 80-year-old Alzheimer's patient regained speech and continence after taking 5g of psilocybin, an Alzheimer's experimental drug The post An Alzheimer’s Patient Recovered Speech a...

ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Ther...

Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapies

Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.

Parkinson’s Drug Restores Memories in Alzheimer’s

Severe dopamine dysfunction in the entorhinal cortex is a primary, hidden mechanism behind Alzheimer's-related memory impairment. Researchers found that dopamine levels in this vit...

Simple Blood Test May Help Detect And Stage Alzheimer's Disease

TUESDAY, June 2, 2026 — Scientists may be one step closer to staging Alzheimer's disease with a simple blood test.The test could offer a cheaper, less invasive alternative to brai...

Scientists found a new Alzheimer’s trigger and a drug that stops it

Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cel...

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

Study Aims to Stop Alzheimer’s Inflammation in APOE4 Carriers

The project uses artificial intelligence and small-molecule targeting to inhibit the cPLA2 enzyme, providing a novel pathway to shut down brain inflammation in high-risk APOE4 gene...

Huge study of Alzheimer’s genetics identifies new drug targets

Almost 50 more genes have been flagged as being linked to Alzheimer’s, along with changes in activity in crucial cells that disappear as dementia progresses

New Alzheimer’s Discovery Could Change How Scientists Fight the Disease

Researchers have uncovered a previously underappreciated mechanism involved in Alzheimer’s disease and developed a compound that interrupts it. For decades, Alzheimer’s research ha...